Long-term denosumab therapy safe for patients with breast, prostate cancer

Long-term denosumab therapy safe for patients with breast, prostate cancer

No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases.

ADT impacts mood of patients with prostate cancer, as perceived by partners

ADT impacts mood of patients with prostate cancer, as perceived by partners

Androgen deprivation therapy negative impacts the mood of patients with prostate cancer.

Prostate cancer not likely to be cause of death in men with low-risk disease

Prostate cancer not likely to be cause of death in men with low-risk disease

Relatively unaggressive prostate tumors are not likely to develop into metastatic disease or result in death.

New biomarker in breast and prostate cancer may help identify patients who will respond to taxanes

Researchers have pinpointed a novel genetic biomarker responsible for the progression of many breast and prostate cancers.

Risk of cancer in the prostate gland may be caused by exposure to bisphenol A (BPA) during organ development

A prostate organoid grown from human embryonic stem cells has enabled researchers to show that exposure to bisphenol A (BPA) may increase prostate cancer risk.

Molecular tinkering doubles cancer drug's efficacy

By surrounding molecules of paclitaxel with self-assembling spheres composed of amino acids, researchers doubled tumor exposure to the drug and reduced its effects on healthy tissue.

Prostate cancer treatment is trending toward risk-specific therapies

Patients receiving treatment for prostate cancer are now more likely to receive medical care matched to their level of risk.

Radiotherapy costs vary among Medicare patients with breast, lung, prostate cancers

Radiotherapy costs vary among Medicare patients with breast, lung, prostate cancers

Cost of radiotherapy among Medicare patients varied most widely because of year of diagnosis, location of treatment, clinic type, and provider.

Study findings do not support association between prostate cancer incidence and shift work

Shift workers do not develop prostate cancer more frequently than their day-shift colleagues, research indicates.

Genomic fingerprint may predict aggressive prostate cancer in African Americans

Genomic fingerprint may predict aggressive prostate cancer in African Americans

African American men are more likely to develop prostate cancer than European American men, and are also more than twice as likely to die from it.

Comparison of zoledronic acid dosing schedules finds less frequent schedule noninferior

Comparison of zoledronic acid dosing schedules finds less frequent schedule noninferior

ASCO 2015: 12-week dosing schedule of zoledronic acid is noninferior to a more-frequent schedule of every 4 weeks.

Researchers identify lynchpin molecule for prostate cancer metastasis

Researchers identify lynchpin molecule for prostate cancer metastasis

A single molecule appears to be the central regulator driving metastasis in prostate cancer.

Black men twice as likely to die from prostate cancer compared to white men

Black men twice as likely to die from prostate cancer compared to white men

Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men.

Research findings differentiate prostate cancer tumors into five different types

Research findings differentiate prostate cancer tumors into five different types

Prostate cancer has five distinct types, with different ways to determine which type of tumor a patient has.

Sensor technology can improve accuracy of prostate cancer diagnosis

Sensor technology can improve accuracy of prostate cancer diagnosis

A sensor chip, able to pick up on differences in glycoprotein molecules, can improve accuracy and efficiency of prostate cancer diagnosis.

More patients with prostate cancer being treated appropriately based on risk

More patients with prostate cancer being treated appropriately based on risk

Patients with prostate cancer are now more likely to receive medical care matched to risk level.

Low-risk prostate cancer cases often upgraded at prostatectomy

Low-risk prostate cancer cases often upgraded at prostatectomy

A recent study indicates a high rate of clinical upgrading at prostatectomy, based on over ten thousand patients reviewed.

Dose-escalated radiation does not benefit patients with low-risk prostate cancer

Dose-escalated radiation does not benefit patients with low-risk prostate cancer

Higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer.

Surveillance being utilized more for prostate cancer

Surveillance being utilized more for prostate cancer

Many men with low-risk disease being spared prostatectomy, radiation, and androgen deprivation monotherapy in favor of active surveillance.

Expectant management of very low-, low-risk prostate cancer is effective, but underused

Expectant management of very low-, low-risk prostate cancer is effective, but underused

Using watchful waiting or active surveillance to monitor men with very low- and low-risk prostate cancer is effective in many patients with localized tumors and could prevent aggressive and unnecessary treatments.

Rate of new prostate cancer diagnoses drops

Rate of new prostate cancer diagnoses drops

New diagnoses of prostate cancer have declined in the U.S. following the 2011 USPSTF draft recommendation regarding the use of prostate-specific antigen (PSA)-based screenings.

Age-adjusted comorbidity score stratifies mortality in prostate cancer

Age-adjusted comorbidity score stratifies mortality in prostate cancer

Age-adjusted prostate cancer-specific comorbidity index is strongly predictive of other-cause mortality, according to recent study data.

Chemotherapy may be the preferred option for some patients with advanced prostate cancer

Chemotherapy may be the preferred option for some patients with advanced prostate cancer

In a small clinical trial, scientists found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.

New evidence demonstrates link between smoking, prostate cancer prognosis

New evidence demonstrates link between smoking, prostate cancer prognosis

Association between smoking and development of various forms of cancer well established; however, evidence of prostate cancer link contradictory.

Study shows significant decline in prostate cancer diagnoses

Study shows significant decline in prostate cancer diagnoses

Prostate cancer diagnoses in the United States dropped 28% in year following USPSTF draft recommendation.

Western diet may increase risk of death after prostate cancer diagnosis

Adopting or retaining a Western-style diet after a prostate cancer diagnosis does little to improve cancer-related mortality or overall mortality, when compared to a healthier diet.

Chemo may be preferred option for some with advanced prostate cancer

Chemo may be preferred option for some with advanced prostate cancer

Men with advanced prostate cancer who possess AR-V7 respond just as well to chemotherapy as those who lack AR-V7.

Emotional distress may motivate patients to undergo prostate cancer surgery unnecessarily

Emotional distress may motivate patients to undergo prostate cancer surgery unnecessarily

Emotionally distressed men diagnosed with prostate cancer may be more likely to opt for surgery.

Novel test combines two markers with prostate-specific antigen (PSA) for improved prostate cancer detection

Novel test combines two markers with prostate-specific antigen (PSA) for improved prostate cancer detection

A new test that employs urine analysis demonstrated improved prostate cancer detection over traditional models based on prostate-specific antigen (PSA) levels.

Fee-for-service health care may lead to higher risks in robotic prostate surgery

Hospitals may invest in expensive, robot-assisted surgical models for performing radical prostatectomies (RARPs), but patients may benefit more from an experienced surgeon performing traditional open surgery.

Cancer survivors have evolving information needs

Depending on the type of cancer faced, the needs of survivors can vary.

Androgen deprivation therapy may lead to cognitive impairment in prostate cancer patients

Men who are receiving androgen deprivation therapy (ADT) have an increased chance of experiencing impaired cognitive function.

Optimal Sequencing for Chemotherapy and Radium 223 for Prostate Cancer Under Debate

Optimal Sequencing for Chemotherapy and Radium 223 for Prostate Cancer Under Debate

When is chemotherapy or radium 223 the optimal treatment for men with advanced prostate cancer?

Why do some prostate cancer patients experience more hot flashes?

Why do some prostate cancer patients experience more hot flashes?

Researchers are examining what factors might make patients with prostate cancer more likely to experience hot flashes during and after therapy.

Combined radiation and hormone therapy improves survival in node-positive prostate cancer

Combined radiation and hormone therapy improves survival in node-positive prostate cancer

Men with prostate cancer that has spread to nearby lymph nodes may find the addition of radiation therapy to treatments that block the effects of testosterone beneficial.

BRCA-targeting drug has benefit in prostate cancer

Trials results indicate that the pioneering drug olaparib, which targets inherited mutations, can be beneficial for men with prostate cancer.

ASCO: Docetaxel with hormone therapy may improve outcomes

ASCO: Docetaxel with hormone therapy may improve outcomes

Combination of docetaxel and hormone therapy can extend life by almost a year for prostate cancer patients, according to new research.

Unemployment associated with increase in prostate cancer-associated deaths

Unemployment associated with increase in prostate cancer-associated deaths

Rises in unemployment are associated with increases in deaths due to prostate cancer.

Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy

Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy

[Clinical Medicine Insights] In this case study, a 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk‑3 gene.

Men treated with ADT more likely to experience impaired cognitive performance

Men treated with ADT more likely to experience impaired cognitive performance

Men treated with androgen deprivation therapy (ADT) for prostate cancer more likely to demonstrate impaired cognitive performance.

Permanent radiotherapy implants reduce risk of prostate cancer recurrence after 5 years

The use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer doubled the chances of those individuals to be cancer-free 5 years later.

Hormonal therapy plus radiation increases survival in node-positive prostate cancer

Hormonal therapy plus radiation increases survival in node-positive prostate cancer

Addition of radiotherapy to hormonal therapy may improve survival in men with node-positive prostate cancer.

Patients with prostate cancer receiving hormone therapy may benefit from statins

Patients with prostate cancer receiving hormone therapy may benefit from statins

Statin use may slow prostate cancer progression in patients receiving androgen deprivation therapy, but more trials are needed to confirm benefits, researchers say.

Statin drugs deny prostate cancer cells access to needed hormones, delaying disease progression

Statin drugs deny prostate cancer cells access to needed hormones, delaying disease progression

Statins were shown to delay disease progression in men with prostate cancer when statins were also initiated with androgen deprivation therapy (ADT).

Treating periodontal disease may reduce prostate inflammation

Treating periodontal disease may reduce prostate inflammation

Treating gum disease reduced symptoms of prostate inflammation.

Use of postsurgical radiotherapy for prostate cancer declining despite evidence of benefit

Postsurgical radiation therapy for prostate cancer at risk of recurrence is declining in the United States, despite evidence that it can be helpful.

Under- and over-imaging suspected in prostate cancer care

Under- and over-imaging suspected in prostate cancer care

For men with nonmetastatic castration resistant prostate cancer with a negative bone scan after diagnosis, factors associated with a second bone scan include higher PSA, shorter PSA doubling time, and faster PSA velocity; but under- and over-imaging may also be a factor.

Study finds $1 test using gold nanoparticles outperforms PSA screen for prostate cancer

Study finds $1 test using gold nanoparticles outperforms PSA screen for prostate cancer

An inexpensive, quick-result test has been shown in recently published studies to be more sensitive and more exacting than the current standard test for early stage prostate cancer.

Brachytherapy decreases risk of prostate cancer five-year recurrence

Brachytherapy decreases risk of prostate cancer five-year recurrence

Men with prostate cancer who received permanent radioactive implants (brachytherapy) were twice as likely to be cancer-free 5 years later.

Implementing decision aids affects care decisions in urology

Implementation of video-based decision aids for men lowered rates of elective surgery for benign prostatic hyperplasia (BPH) and decreased rates of active treatment for localized prostate cancer.

Sweeping prostate cancer review upends widely held belief on radiation after surgery

Two studies do not show protective effect of delayed radiation compared to earlier radiation for prostate cancer.

Aspirin use does not reduce prostate cancer mortality

Aspirin use does not reduce prostate cancer mortality

Post-diagnostic aspirin use is not associated with a decreased risk of prostate cancer outcomes, according to study data.

Resistance, aerobic exercise improves quality of life in older long-term survivors of prostate cancer

Resistance, aerobic exercise improves quality of life in older long-term survivors of prostate cancer

Aerobic and resistance exercise appears to have beneficial effects on health-related quality of life (HRQoL).

Fitness level associated with lower risk of some cancers and death in men

A higher fitness level leads to decreased risk of lung and colorectal cancer for men.

Are decisions on treatment choices for prostate cancer shared by doctor and patient?

Truly shared decision-making is possible only when the patient understands everything the treatment options entail, and the doctor understands the patient's personal situation and desires.

Prostate cancer survivors benefit from non-vigorous activity, walking

Prostate cancer survivors benefit from non-vigorous activity, walking

After prostate cancer diagnosis, at least five hours of non-vigorous activity or 3 hours of walking is beneficial.

Vitamin D and prostate cancer: Higher intake improves active surveillance outcomes

Vitamin D and prostate cancer: Higher intake improves active surveillance outcomes

Bruce W. Hollis, PhD, discusses the findings from his study on the benefits of increasing vitamin D intake in patients with prostate cancer undergoing active surveillance.

Levofloxacin plus aminoglycoside superior to ciprofloxacin after prostate biopsy

Levofloxacin plus aminoglycoside superior to ciprofloxacin after prostate biopsy

Use of single dose of fluoroquinoloneis optimal prophylaxis to reduce infectious complications in patients undergoing prostate biopsy.

Aspirin not associated with decreased prostate cancer-associated mortality

Aspirin not associated with decreased prostate cancer-associated mortality

Aspirin use does not decrease the risk of mortality associated with prostate cancer.

Incidence, risk factors of injection site reactions with degarelix investigated

Incidence, risk factors of injection site reactions with degarelix investigated

Investigators sought to determine the incidence of injection site reactions (ISRs) after administration of degarelix.

Effective management of dietary cholesterol may prevent metastasis in patients with prostate cancer

Effective management of dietary cholesterol may prevent metastasis in patients with prostate cancer

New findings from researchers in Australia indicate dietary measures may prevent metastasis of prostate cancer.

Inappropriate breast and prostate imaging of Medicare beneficiaries examined

An association of high rates of inappropriate imaging for prostate cancer and breast cancer found in a study of Medicare beneficiaries suggests that regional culture could contribute to inappropriate imaging.

Prostate cancer recurrence after surgery is nearly double in smokers

Prostate cancer recurrence after surgery is nearly double in smokers

Current smokers and those who quit less than 10 years previously are at higher risk of prostate cancer recurrence after surgery.

Vitamin D may slow progression of low-grade prostate tumors

Vitamin D may slow progression of low-grade prostate tumors

Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery.

Androgen receptor abnormality may not affect response to chemotherapy

Study findings suggest that androgen receptor V7 (AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer.

Active surveillance of intermediate-risk prostate cancer associated with decreased survival

An analysis of data on 945 patients with prostate cancer followed with active surveillance displayed outcome differences, depending on whether the patient was low- or intermediate-risk at diagnosis.

Omega-3 fatty acids may inhibit prostate cancer cell growth

Omega-3 fatty acids may inhibit prostate cancer cell growth

A mechanism in omega-3 fatty acids may inhibit the growth and spread of prostate cancer cells.

Family history of prostate cancer may indicate higher risk of breast cancer in women

A family history of prostate cancer among first-degree relatives may increase a woman's risk of developing breast cancer, according to a new study.

Nanotechnology could help with prostate cancer treatment options

Nanotechnology could help with prostate cancer treatment options

Novel nanotechnology could help men with prostate cancer make better decisions in treatment options.

Statins may slow prostate cancer progression

Statins may slow prostate cancer progression

Findings among men taking a statin alongside androgen deprivation therapy showed additional months of progression-free survival.

Regional infrastructure tied to inappropriate breast, prostate cancer imaging

Regional infrastructure tied to inappropriate breast, prostate cancer imaging

Regional infrastructure could contribute to inappropriate imaging in patients at risk for prostate and breast cancer.

No correlation found between vitamin D variations and fatal prostate cancer

No correlation found between vitamin D variations and fatal prostate cancer

Neither circulating 25-hydroxyvitamin D (25[OH]D) levels nor common variations in vitamin D pathway genes appear to be associated with risk of fatal prostate cancer, according to recent research.

Early evidence of increase in higher-risk prostate cancer deaths seen in analysis of data

A retrospective analysis of patient data found the proportion of men with diagnoses of intermediate- and high-risk prostate cancer increased by nearly 6% between 2011 and 2013.

History of prostate cancer in relatives may increase risk of breast cancer

History of prostate cancer in relatives may increase risk of breast cancer

Women with a family history of prostate cancer in first-degree relatives may have a higher risk of developing breast cancer.

ASCO: High-risk prostate cancer diagnosis up since new PSA recommendations

ASCO: High-risk prostate cancer diagnosis up since new PSA recommendations

Researchers report 3 percent annual rise in intermediate- and high-risk cases

Two major studies strengthen case for prostate cancer drug before chemotherapy

The pioneering prostate cancer drug abiraterone can significantly extend the lives of men with advanced prostate cancer if administered prior to administering chemotherapy, according to phase III clinical trial data.

Study may support active surveillance for favorable intermediate-risk prostate cancer

New research suggests that active surveillance may be an initial approach for men with favorable intermediate-risk prostate cancer.

Most commonly used treatment for prostate cancer is radiotherapy

A recent study has determined that radiation therapy is the most common treatment for prostate cancer regardless of cancer stage, PSA level, or prognosis and risk rating.

Patients with detectable PSA after prostatectomy should receive more aggressive radiation therapy

Patients with detectable PSA after prostatectomy should receive more aggressive radiation therapy

Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy are advised to receive more aggressive radiation therapy treatment, according to a study.

Black men have lower preference for investigation of prostate cancer

Black men have lower preference for investigation of prostate cancer

Black men are less willing to be investigated for prostate cancer, thereby increasing the likelihood of being diagnosed.

ASCO: Active surveillance for prostate cancer may decrease survival odds for some

ASCO: Active surveillance for prostate cancer may decrease survival odds for some

When active surveillance is chosen, survival for intermediate-risk disease may be decreased.

ASCO: Testicular cancer history may indicate greater risk of developing prostate cancer

ASCO: Testicular cancer history may indicate greater risk of developing prostate cancer

Individuals who've had testicular cancer may be at increased risk for prostate cancer, but the overall risk is low, according to a study.

Radiation therapy used most often for prostate cancer regardless of decision-making factors

Radiation therapy used most often for prostate cancer regardless of decision-making factors

Most common treatment for prostate cancer is radiation therapy, regardless of cancer stage.

Considerable practice variation among surgeons in selecting patients for radical prostatectomy

Considerable practice variation among surgeons in selecting patients for radical prostatectomy

Variation was observed at a high-volume center when surgeons selected patients with low-risk prostate cancer to undergo radical prostatectomy, according to a study.

Drug combination suppresses growth of late-stage prostate cancer tumors

Low doses of metformin and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors.

Observation used increasingly in younger men with prostate cancer

Observation used increasingly in younger men with prostate cancer

From 2004 to 2009, marked increase in observation among men with low-risk prostate cancer has been observed.

ASCO endorses ACS recommendations for prostate cancer survivor care

ASCO endorses ACS recommendations for prostate cancer survivor care

Guideline outlines recommended follow-up care for prostate cancer survivors

Smoking linked to breast and prostate cancer

Smoking linked to breast and prostate cancer

Smoking is associated with an increased risk of breast cancer, prostate cancer, and routine infections.

Targeted MRI-ultrasound is better than standard biopsy at detecting high-risk prostate cancer

Targeted magnetic resonance (MR)/ultrasound fusion biopsy outperformed standard biopsy technique for increased detection of high-risk prostate cancer, according to a recent study.

Factors associated with emotional distress in newly-diagnosed prostate cancer identified

Factors associated with emotional distress in newly-diagnosed prostate cancer identified

Researchers identified certain factors associated with emotional distress in men with newly diagnosed prostate cancer.

Abiraterone improves survival in prostate cancer when given before chemo

Abiraterone improves survival in prostate cancer when given before chemo

Abiraterone significantly extends survival in men with advanced prostate cancer (PCa) if administered before chemotherapy.

New strategy proposed to overcome treatment resistance in prostate cancer

Researchers have identified two genes that appear to be simultaneously overexpressed in aggressive prostate cancers resistant to the androgen-targeted treatments enzalutamide and abiraterone acetate.

PDE-5 inhibitors linked to prostate cancer biochemical recurrence

PDE-5 inhibitors linked to prostate cancer biochemical recurrence

Phosphodiesterase type 5 inhibitors up the risk of biochemical recurrence after radical prostatectomy, according to a recent study.

Combination prostate biopsy could yield improved results

Combination prostate biopsy could yield improved results

Prostate biopsies that combine both magnetic resonance imaging (MRI) technology and ultrasound appear to give more accurate results, according to a new study.

Current smoking lowers survival odds for prostate cancer

Current smoking lowers survival odds for prostate cancer

Former, as well as current, smokers saw higher risk for disease recurrence and radiation therapy-related urinary side effects.

PDE-5 inhibitors increase risk of biochemical recurrence after radical prostatectomy

PDE-5 inhibitors increase risk of biochemical recurrence after radical prostatectomy

Taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of recurrence.

Smoking Increases Side Effect, Recurrence Risk in Prostate Cancer

Smoking Increases Side Effect, Recurrence Risk in Prostate Cancer

Recent study confirmed the effects on smoking on patients with prostate cancer.

New study helps physicians and patients determine prostate cancer risk

New study helps physicians and patients determine prostate cancer risk

Examining more distant relations for prostate cancer can provide important patient history.

Study examines vaccine therapy in prostate cancer with rising prostate-specific antigen (PSA) levels

A vaccine therapy designed to boost the body's immune response may join available early treatment options for prostate cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs